Cogent Biosciences, Inc. (COGT)
NASDAQ:COGT
Want to see COGT full AI Analyst Report?
COGT Stock Chart & Stats
$37.25
-$0.07(-0.91%)
At close: 4:00 PM EST
$37.25
-$0.07(-0.91%)
Day’s Range― - ―
52-Week Range$7.03 - $43.73
Previous CloseN/A
Volume181.15K
Average Volume (3M)2.19M
Market Cap
$6.20B
Enterprise Value$5.75B
Total Cash (Recent Filing)$866.38M
Total Debt (Recent Filing)$238.65M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Aug 11, 2026EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.08
Shares Outstanding170,868,010
10 Day Avg. Volume2,313,315
30 Day Avg. Volume2,193,920
Financial Highlights & Ratios
PEG Ratio-3.81
Price to Book (P/B)3.77
Price to Sales (P/S)0.00
P/FCF Ratio-9.03
Enterprise Value/Market Cap0.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.65K
Enterprise Value/Ebitda-16.41
Forecast
1Y Price Target
$52.43Price Target Upside40.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.25
Revenue Forecast (FY)$10.85M
Bulls Say, Bears Say
Bulls Say
Balance-sheet Equity CushionSizable equity relative to assets provides a multi-quarter capital buffer that supports ongoing clinical programs and R&D spending. This reduces near-term insolvency risk versus peers, giving management time to advance trials before raising dilutive capital, preserving strategic optionality.
Governance Stability And OversightStrong shareholder support for the board and auditor signals continuity in leadership and financial oversight. Stable governance reduces execution risk on lengthy development programs, bolsters credibility with investors and potential partners, and aids consistent strategic execution.
Focused Precision-medicine PipelineA targeted strategy against genetically defined, KIT-altered malignancies concentrates resources on high-value patient subsets. This focus can raise trial efficiency, enable clearer regulatory pathways and commercial differentiation, improving long-term odds of a successful, sellable therapy.
Bears Say
No Revenue; Widening Net LossesAbsence of revenue combined with rapidly expanding net losses shows the company remains pre-commercial with growing spending. Persistent losses increase the probability management must raise capital, diluting shareholders and stressing long-term viability unless clinical milestones materially de-risk the programs.
High And Rising Cash BurnSteep, increasing operating and free cash outflows indicate the company consumes significant capital to advance programs. Sustained burn shortens runway, forces financing at potentially unfavorable terms, and may necessitate program cuts or slower development pacing absent milestone-based funding.
Increasing Leverage Vs Prior PeriodsDebt rising from previously low levels increases financial risk while operating losses persist. Higher leverage reduces flexibility for opportunistic investments, elevates refinancing and covenant risks, and compounds dilution pressure if equity issuance is required to shore up capital.
Cogent Biosciences News
COGT FAQ
What was Cogent Biosciences, Inc.’s price range in the past 12 months?
Cogent Biosciences, Inc. lowest stock price was $7.03 and its highest was $43.73 in the past 12 months.
What is Cogent Biosciences, Inc.’s market cap?
Cogent Biosciences, Inc.’s market cap is $6.20B.
When is Cogent Biosciences, Inc.’s upcoming earnings report date?
Cogent Biosciences, Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 47 days.
How were Cogent Biosciences, Inc.’s earnings last quarter?
Cogent Biosciences, Inc. released its earnings results on May 05, 2026. The company reported -$0.53 earnings per share for the quarter, beating the consensus estimate of -$0.533 by $0.003.
Is Cogent Biosciences, Inc. overvalued?
According to Wall Street analysts Cogent Biosciences, Inc.’s price is currently Undervalued.
Does Cogent Biosciences, Inc. pay dividends?
Cogent Biosciences, Inc. does not currently pay dividends.
What is Cogent Biosciences, Inc.’s EPS estimate?
Cogent Biosciences, Inc.’s EPS estimate is -0.56.
How many shares outstanding does Cogent Biosciences, Inc. have?
Cogent Biosciences, Inc. has 170,868,010 shares outstanding.
What happened to Cogent Biosciences, Inc.’s price movement after its last earnings report?
Cogent Biosciences, Inc. reported an EPS of -$0.53 in its last earnings report, beating expectations of -$0.533. Following the earnings report the stock price went up 0.681%.
Which hedge fund is a major shareholder of Cogent Biosciences, Inc.?
Currently, no hedge funds are holding shares in COGT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cogent Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$52.43 (40.75% Upside)
$52.43 (40.75% Upside)
Blogger Sentiment
Bullish
COGT Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 4.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $242.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
400.13%
12-Months-Change
Fundamentals
Return on Equity
-83.29%
Trailing 12-Months
Asset Growth
218.19%
Trailing 12-Months
Company Description
Cogent Biosciences, Inc.
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
COGT Stock 12 Month Forecast
Average Price Target
$52.43
▲(40.75% Upside)
Technical Analysis
IDEAYA Biosciences
―
Beam Therapeutics
―
Disc Medicine
―
Harmony Biosciences Holdings
―
Immunocore Holdings
―
Ownership Overview
4.03% Insiders
30.38% Mutual Funds
44.21% Other Institutional Investors
5.72% Public Companies and
Individual Investors